Continuous intrathecal baclofen delivery in severely disabling spasticity
Abstract
Background/Aim. Spasticity is the consequence of several clinical conditions including cerebral palsy, brain injury, spinal cord injury, multiple sclerosis, aneurysm bleeding, and some other neurological disorders. The aim of this study was to determine the efficacy of intrathecal baclofen (ITB) treatment in medically intractable severely disabling spasticity and present the challenges encountered during pump implantation surgery on these patients. Methods. The patients who underwent intrathecal baclofen pump implantation surgery between the years 2012 and 2015 with minimum follow-up of six months were recruited from the clinic archives. Twenty two patients with severe spasticity who had Modified Asworth Spasticity Scale (MASS) score of 3 or 4 were enrolled in our series. Eight of twenty-two patients were at pediatric age and they all were non-ambulant before surgery. Results. All of the patients underwent programmable intrathecal baclofen pump implantation surgery. Catheters were placed via percutaneous technique into to the subarachnoid space in 18 patients while, we had to perform partial hemi-laminectomy in order to place the catheters in 4 patients. All the patients improved significantly and 5 began using upper extremities and 3 adults became ambulant following physical therapy. Mean of the MASS scores improved from 3.59 to 1.32 (p < 0.001). Conclusion. The ITB therapy obviously increased quality of life and functional outcome in patients with disabling spasticity. As a result, physical treatment was more useful for these patients. Although some spinal abnormalities due to spasticity may necessitate partial hemilaminectomy to implant the pump, patients with intractable spasticity should be given the chance of intrathecal baclofen treatment at the earliest period of their lifetime disability.
References
Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol 2009; 11(3): 153–61.
Lance JW. What is spasticity? Lancet 1990; 335(8689): 606.
Anderson WS, Jallo GI. Intrathecal Baclofen Therapy and the Treatment of Spasticity. Neurosurgery Quarterly 2007; 17(3): 185–192.
Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1984; 1(8385): 1078.
Pin TW, McCartney L, Lewis J, Waugh M. Use of intrathecal ba-clofen therapy in ambulant children and adolescents with spas-ticity and dystonia of cerebral origin: A systematic review. Dev Med Child Neurol 2011; 53(10): 885–95.
Plassat R, Perrouin VB, Menei P, Menegalli D, Mathé JF, Richard I. Treatment of spasticity with intrathecal Baclofen admin-istra¬tion: Long-term follow-up, review of 40 patients. Spinal Cord 2004; 42(12): 686–93.
Guillaume D, Van Havenbergh A, Vloeberghs M, Vidal J, Roeste G. A clinical study of intrathecal baclofen using a programma-ble pump for intractable spasticity. Arch Phys Med Rehabil 2005; 86(11): 2165–71.
Coffey JR, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, et al. Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long-term multicenter study. J. Neurosurg 1993; 78(2): 226–32.
Baker KW, Tann B, Mutlu A, Gaebler-Spira D. Improvements in children with cerebral palsy following intrathecal baclofen: Use of the Rehabilitation Institute of Chicago Care and Com-fort Caregiver Questionnaire (RIC CareQ). J Child Neurol 2014; 29(3): 312–7.
Borowski A, Pruszczynski B, Miller F, Synder M. Quality of life in cerebral palsy children treated with intrathecal baclofen pump implantation in parents' opinion. Chir Narzadow Ruchu Ortop Pol 2010; 75(5): 318–22. (Polish)
Stempien L, Tsai T. Intrathecal baclofen pump use for spastici-ty: A clinical survey. Am J Phys Med Rehabil 2000; 79(6): 536–41.
Dario A, Scamoni C, Bono G, Ghezzi A, Zaffaroni M. Functional improvement in patients with severe spinal spasticity treated with chronic intrathecal baclofen infusion. Funct Neurol 2001; 16(4): 311–5.
Hansen CR, Gooch JL, Such-Neibar T. Prolonged, severe in-trathe¬cal baclofen withdrawal syndrome: A case report. Arch Phys Med Rehabil 2007; 88(11): 1468–71.
Shirley KW, Kothare S, Piatt JH, Adirim TA. Intrathecal baclo-fen overdose and withdrawal. Pediatr Emerg Care 2006; 22(4): 258–61.
Watve SV, Sivan M, Raza WA, Jamil FF. Management of acute overdose or withdrawal state in intrathecal baclofen therapy. Spinal Cord 2012; 50(2): 107–11.
Phillips MM, Miljkovic N, Ramos-Lamboy M, Moossy JJ, Horton J, Buhari AM, et al. Clinical Experience With Continuous In-trathecal Baclofen Trials Prior to Pump Implantation. PM R 2015; 7(10): 1052–8.
Gooch JL, Oberg WA, Grams B, Ward LA, Walker ML. Care pro¬vider assessment of intrathecal baclofen in children. Dev Med Child Neurol 2004; 46(8): 548–52.
Gray N, Morton RE, Brimlow K, Keetley R, Vloeberghs M. Goals and outcomes for non ambulant children receiving continuous infusion of intrathecal baclofen. Eur J Paediatr Neurol 2012; 16(5): 443–8.
McCoy AA, Fox MA, Schaubel DE, Ayyangar RN. Weight gain in children with hypertonia of cerebral origin receiving in-trathecal baclofen therapy. Arch Phys Med Rehabil 2006; 87(11): 1503–8.
Krach LE. Intrathecal baclofen use in adults with cerebral pal-sy. Dev Med Child Neurol 2009; 51(Suppl 4): 106–12.
Ginsburg GM, Lauder AJ. Progression of scoliosis in patients with spastic quadriplegia after the insertion of an intrathecal baclofen pump. Spine (Phila Pa 1976) 2007; 32(24): 2745–50.
Gerszten PC, Albright AL, Johnstone GF. Intrathecal baclofen infu¬sion and subsequent orthopedic surgery in patients with spastic cerebral palsy. J Neurosurg 1998; 88(6): 1009–13.
Gooch JL, McFadden M, Oberg W. Orthopedic surgery in chil-dren with intrathecal baclofen pumps. J Pediatr Rehabil Med 2013; 6(4): 233–8.
Nance P, Schryvers O, Schmidt B, Dubo H, Loveridge B, Fewer D. In¬trathecal baclofen therapy for adults with spinal spasticity: Therapeutic efficacy and effect on hospital admissions. Can J Neurol Sci 1995; 22(1): 22–9.